Browsing Tag
Diabetes
59 posts
Why Eli Lilly (NYSE: LLY) just joined the $1tn club—and what it means for obesity drug stocks
Find out how Eli Lilly’s weight-loss drug surge has pushed it past a $1 trillion valuation—and what that means for the industry!
From GLP-1 to FGF21: How Novo Nordisk’s Akero Therapeutics deal signals a new era in metabolic drug dominance
Novo Nordisk’s $5.2 B Akero deal adds the FGF21 drug efruxifermin to its MASH portfolio. See how it expands the company’s metabolic dominance.
Virginia awards $3mn to Civica to accelerate affordable insulin manufacturing at Petersburg plant
Virginia awards $3M to Civica to accelerate affordable insulin production at its Petersburg plant, supporting U.S. diabetes care access and local biotech growth.
How does catharanthus roseus help in treating cancer and other chronic diseases?
Discover how Catharanthus roseus (Madagascar Periwinkle) contributes to modern cancer treatment and traditional medicine through its powerful phytochemicals.
How Novo Nordisk is building a post-semaglutide strategy: Inside its metabolic pipeline and innovation bets
Novo Nordisk pivots beyond semaglutide with amycretin, CagriSema, and oral GLP-1 therapies. See how it’s building its next-generation obesity drug platform.
Replacing diet drinks with water more than doubles type 2 diabetes remission in women, ADA 2025 study shows
A new ADA 2025 study shows that women with type 2 diabetes who replaced diet drinks with water saw 90% remission rates and greater weight loss outcomes.
Gan & Lee Pharmaceuticals reveals competitive Phase 2 results for bofanglutide and GZR4 at ADA 2025 sessions
Gan & Lee Pharmaceuticals presented strong Phase 2 results for bofanglutide and GZR4 in type 2 diabetes, advancing its long-acting diabetes pipeline.
Diabetes and hypoglycemia explained: Symptoms, diagnosis, treatment, and daily management
Discover how diabetes and hypoglycemia affect your health, how to detect symptoms early, and the latest approaches to managing blood sugar effectively.
Gan & Lee Pharmaceuticals begins US Phase 2 trial of bofanglutide for obesity and weight management
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) has initiated its Phase 2 clinical trial of bofanglutide (GZR18)…
Biocon Biologics strengthens US market presence with Civica insulin deal
As insulin prices remain a pressing concern in the United States, Biocon Biologics collaboration with Civica, Inc. has…